Education
About Us
Working with TipRanks
Follow Us
Isofol Medical AB (SE:ISOFOL)
:ISOFOL
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr2.14
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr187.50M
Enterprise Valuekr152.68M
Total Cash (Recent Filing)kr126.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,107,240
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage (no Debt)A zero-debt capital structure materially lowers financial risk and interest burden, giving management flexibility to fund clinical programs and negotiate partner deals. Over 2–6 months this durable low leverage reduces solvency pressure and improves options for non-dilutive or partnership financing.
Improved Cash Burn TrendMarked reduction in operating cash outflows versus earlier years signals better cost discipline and program prioritization. That structural improvement lengthens runway per unit of capital raised, lowering near-term refinancing frequency and making it easier to reach clinical/regulatory inflection points with less dilution.
Focused Clinical-stage, Partner-focused Business ModelA lean, development-and-partnering model concentrates resources on advancing a single lead asset, limiting commercial build costs. This durable strategy suits small biotech—reducing fixed costs, enabling licensing or co-development, and improving scalability if clinical data supports partnering or out-licensing.
Bears Say
No Recent RevenueA cessation of revenue leaves the company fully pre-commercial and dependent on external capital to fund operations. Over a multi-month horizon this structural lack of product sales magnifies funding risk, limits reinvestment capacity, and makes operational continuity contingent on successful financing or partner deals.
Persistent And Sizable Net LossesOngoing annual net losses and ~-51.9M operating cash burn in 2025 indicate continued negative cash conversion. Structurally, sustained losses increase the frequency and size of required capital raises, dilute shareholders, and constrain ability to expand the pipeline or finance late-stage trials without outside funding.
Eroding Equity CushionMaterial decline in shareholders' equity over several years reflects accumulated losses and financing activity. This weaker capital buffer reduces capacity to absorb setbacks or extend operations without dilution, raising structural funding vulnerability and potentially weakening negotiation leverage with partners or lenders.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr2.14 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr187.50M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 73 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 281,107,240 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.13%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―